Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.
about
Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndromeGuidelines for management of patients with a short bowelDo glucagonomas always produce glucagon?Extensive Intestinal Resection Triggers Behavioral Adaptation, Intestinal Remodeling and Microbiota Transition in Short Bowel SyndromeThe role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetesStructure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptorsChanges in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilitySevere metabolic alkalosis and recurrent acute on chronic kidney injury in a patient with Crohn's disease.Microbiota Is Involved in Post-resection Adaptation in Humans with Short Bowel Syndrome.Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing.Intestinal mucosal adaptation.Differential protein expression during colonic adaptation in ultra-short bowel rats.Modulation of specific intestinal epithelial progenitors by enteric neurons.Can we protect the gut in critical illness? The role of growth factors and other novel approaches.Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2.Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure.Proglucagon-derived peptides: mechanisms of action and therapeutic potential.GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.Gut adaptation and the glucagon-like peptidesAnimal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges.Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.Novel therapies for osteoporosis.The role of gut hormones in glucose homeostasisEmerging treatment options for short bowel syndrome: potential role of teduglutideIntestinal adaptation after massive intestinal resection.Bench-to-bedside review: the gut as an endocrine organ in the critically illEnterogenesis in a clinically feasible model of mechanical small-bowel lengthening.Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.The locally acting glucocorticosteroid budesonide enhances intestinal sugar uptake following intestinal resection in ratsThe medical management of intestinal failure: methods to reduce the severity.Porcine models of digestive disease: the future of large animal translational research.Glucagon-like peptide-2-stimulated protein synthesis through the PI 3-kinase-dependent Akt-mTOR signaling pathway.Intestinal rehabilitation: a management program for short-bowel syndrome.Current issues in the management of intestinal failure.Somatropin for the treatment of short bowel syndrome in adults.Short bowel syndrome: clinical guidelines for nutrition management.New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome.
P2860
Q24629712-3D217C16-4EDB-4E88-AE69-26159A22724CQ24646515-F85FFE36-8548-46D3-8C44-17C4A4BC440CQ26771665-3D00CE5C-0741-4538-A2AE-F0EC2B1BB617Q28076717-1F73434E-2AB8-432E-8FDE-17A6C1F9C249Q28080912-872C944F-D5B0-48A2-BBC0-ED068A001C76Q28203273-F4A29140-30D0-4212-A61B-1F45AD948B8AQ29617378-6BF76F5E-C583-4D74-A990-03D85719E0A7Q33557878-687F425C-955A-4656-8CE5-94773E76B37BQ33575682-23889F16-232D-41E1-8990-E66942397B37Q33694525-D521FEA0-BFB9-4600-BCAA-894FC1543A20Q33867801-E2C270B7-5859-47C3-90AE-5A90CD87E69EQ33919792-2500F05E-E44F-4289-8696-C37E07CC85B5Q33947818-8A00EDB8-F219-4A05-8144-0B2AB370533AQ34014020-DD49E8DF-3D4F-4842-81A0-2ABDFF6E319DQ34281175-6EA7E829-D85E-4564-B9C1-36A5611EFAD3Q34289440-FD5D99E6-486A-4240-A849-5ECE05132539Q34425937-6AA55746-6F36-43BE-8079-FC481E38548AQ34452524-42A0A840-CD59-4C2C-8264-7248E956278FQ34494154-491EED7D-944C-4965-9386-AF56A607118FQ34526042-07660C11-F2AC-43AF-864C-E028A23F93B4Q34726758-EDB4CCE2-E49F-4945-BF86-EC6B1519620AQ35038334-397860B8-C83B-4FAE-A073-13A7E6E335B1Q35091974-632279D8-1A6A-4F15-9982-192FDCAE3195Q35094675-F6406DE3-E6C1-421B-B566-2962E5DB0006Q35251016-3E19D469-42DB-42FB-A751-B5D2D1D4320CQ35304614-CD7E250C-C18E-484D-B1FD-609940C773FDQ35521421-0DA84245-6E0B-48A7-9F76-9FC20C9A7606Q35559137-2D26B733-00F4-4B14-B462-CC2384C14C60Q35575426-498FA406-C081-4D4D-AC5F-377BB7B69664Q35596753-1919F9DD-72BE-4031-AF4D-C7B70F7AB03BQ35597698-61D06AC3-AFF3-4DBD-A853-EC6FD6B22F99Q35598377-32D4DFD6-C404-4500-A938-E25F0294042EQ35614748-A76EF737-9C01-42B3-99C1-6559DA3DF65CQ35691021-0A53FD11-ED40-4B8A-85F9-F7219131D4DBQ35756432-7EB51C1C-61BB-4029-8202-147E76B4C637Q36016254-928E1DC4-3C77-4E8C-A0D0-044BE8EBCC9DQ36121045-DA3F2FEE-DF8E-475E-B98C-9DE9CB94D03EQ36222078-9BC1672A-CB7F-460D-91D3-F35D75750591Q36278442-983BF4ED-FEFF-4076-9FE2-130ECC522731Q36489336-6560E2F2-2D3B-4FFC-B081-5FF3465190BB
P2860
Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Glucagon-like peptide 2 improv ...... -bowel patients with no colon.
@ast
Glucagon-like peptide 2 improv ...... -bowel patients with no colon.
@en
type
label
Glucagon-like peptide 2 improv ...... -bowel patients with no colon.
@ast
Glucagon-like peptide 2 improv ...... -bowel patients with no colon.
@en
prefLabel
Glucagon-like peptide 2 improv ...... -bowel patients with no colon.
@ast
Glucagon-like peptide 2 improv ...... -bowel patients with no colon.
@en
P2093
P50
P356
P1433
P1476
Glucagon-like peptide 2 improv ...... t-bowel patients with no colon
@en
P2093
B S Hansen
J L Madsen
J Thulesen
P B Mortensen
P304
P356
10.1053/GAST.2001.22555
P407
P577
2001-03-01T00:00:00Z